{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:56:45Z","timestamp":1761919005811},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.beha.2007.03.005","type":"journal-article","created":{"date-parts":[[2007,8,18]],"date-time":"2007-08-18T11:16:56Z","timestamp":1187435816000},"page":"545-556","source":"Crossref","is-referenced-by-count":26,"title":["Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"20","author":[{"given":"Michael R.","family":"Grever","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2007.03.005_bib1","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib2","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib3","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.03.005_bib4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2005-05-2093","article-title":"Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia","volume":"107","author":"Mayr","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.cdd.4401194","article-title":"Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy","volume":"10","author":"Sturm","year":"2003","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.beha.2007.03.005_bib6","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2004-11-4516","article-title":"Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL","volume":"106","author":"Austen","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib7","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"Krober","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib8","first-page":"42","article-title":"Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases","volume":"6","author":"Fenaux","year":"1992","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.03.005_bib9","first-page":"246","article-title":"Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis","volume":"6","author":"Fenaux","year":"1992","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.03.005_bib10","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood.V82.11.3452.3452","article-title":"p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1\/MDR3 gene expression","volume":"82","author":"el Rouby","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib11","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V84.9.3148.3148","article-title":"p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies","volume":"84","author":"Wattel","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib12","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1182\/blood.V91.11.4342","article-title":"p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis","volume":"91","author":"Cordone","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/1097-0142(20010115)91:2<285::AID-CNCR1000>3.0.CO;2-X","article-title":"Significance of p53 mutations in patients with chronic lymphocytic leukemia: a sequential study of 30 patients","volume":"91","author":"Barnabas","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2007.03.005_bib14","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.V99.1.300","article-title":"Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage","volume":"99","author":"Stankovic","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib15","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions","volume":"103","author":"Lozanski","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib16","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2005.03.1021","article-title":"Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy","volume":"24","author":"Byrd","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.03.005_bib18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","article-title":"Combination chemoimmunotherapy with pentostatin, cyclophosphamide and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B-chronic lymphocytic leukemia","volume":"109","author":"Kay","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2099.2099","article-title":"Prognostic factors in the UK LRF CLL4 trial","volume":"106","author":"Oscier","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib20","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2006.08.3089","article-title":"Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from a prospective randomized US Intergroup Phase III Trial (E2997)","volume":"25","author":"Grever","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.03.005_bib22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib24","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.03.005_bib25","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/00001622-200011000-00010","article-title":"Campath-1H monoclonal antibody therapy","volume":"12","author":"Flynn","year":"2000","journal-title":"Current Opinion in Oncology"},{"key":"10.1016\/j.beha.2007.03.005_bib26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood.V62.4.873.873","article-title":"Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement","volume":"62","author":"Hale","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib27","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(88)90588-0","article-title":"Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H","volume":"2","author":"Hale","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2007.03.005_bib28","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.1074\/jbc.270.11.6088","article-title":"Primary structure of CD52","volume":"270","author":"Treumann","year":"1995","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.beha.2007.03.005_bib29","first-page":"325","article-title":"CD52 antigen: a review","volume":"7","author":"Domagala","year":"2001","journal-title":"Medical Science Monitor"},{"key":"10.1016\/j.beha.2007.03.005_bib30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2567.1998.00615.x","article-title":"Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells","volume":"95","author":"Rowan","year":"1998","journal-title":"Immunology"},{"key":"10.1016\/j.beha.2007.03.005_bib31","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib32","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1200\/jco.2006.24.18_suppl.6511","article-title":"Preliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL)","volume":"24","author":"Hillmen","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.03.005_bib33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","article-title":"Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy","volume":"347","author":"Stilgenbauer","year":"2002","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.03.005_bib34","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions","volume":"103","author":"Lozanski","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib35","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-003-0710-5","article-title":"High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities","volume":"82","author":"Thornton","year":"2003","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.beha.2007.03.005_bib36","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2006.06.004","article-title":"Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia","volume":"12","author":"Brown","year":"2006","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.beha.2007.03.005_bib37","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2005.04.569","article-title":"Hematopoietic cell transplantation after nonmyeloablative\u00a0conditioning for advanced chronic lymphocytic leukemia","volume":"23","author":"Sorror","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.03.005_bib38","series-title":"Hematology 2002","article-title":"Non-myeloablative transplantation","author":"Maloney","year":"2002"},{"key":"10.1016\/j.beha.2007.03.005_bib39","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2005-08-3372","article-title":"Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study","volume":"107","author":"Delgado","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib40","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1158\/1078-0432.CCR-05-0941","article-title":"Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)","volume":"11","author":"Caballero","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beha.2007.03.005_bib41","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/blood.V96.9.2917","article-title":"CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia","volume":"96","author":"Wierda","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib42","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/blood-2006-04-017749","article-title":"CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53","volume":"108","author":"Dicker","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib43","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood.V92.10.3804","article-title":"Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53","volume":"92","author":"Byrd","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood.V96.2.393","article-title":"Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia","volume":"96","author":"Kitada","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib45","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.leukres.2005.03.010","article-title":"Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity","volume":"29","author":"Flinn","year":"2005","journal-title":"Leukemia Research"},{"key":"10.1016\/j.beha.2007.03.005_bib46","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1158\/1078-0432.CCR-04-2276","article-title":"Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805","volume":"11","author":"Byrd","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beha.2007.03.005_bib47","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib48","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.944.944","article-title":"Flavopiridol, fludarabine and rituximab is a highly active regimen in indolent B-cell lymphoproliferative disorders including mantle cell lymphoma","volume":"106","author":"Lin","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib49","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1182\/blood-2004-07-2713","article-title":"A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival","volume":"105","author":"Alvi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib50","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood-2005-05-1923","article-title":"Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL","volume":"107","author":"Carew","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.03.005_bib51","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/01.cad.0000176501.63680.80","article-title":"Jasmonates\u2014a new family of anti-cancer agents","volume":"16","author":"Flescher","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.beha.2007.03.005_bib52","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1021\/jo040120f","article-title":"Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris","volume":"69","author":"Hwang","year":"2004","journal-title":"The Journal of Organic Chemistry"},{"key":"10.1016\/j.beha.2007.03.005_bib53","first-page":"3349","article-title":"Silvestrol regulates G2\/M checkpoint genes independent of p53 activity","volume":"26","author":"Mi","year":"2006","journal-title":"Anticancer Research"},{"key":"10.1016\/j.beha.2007.03.005_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2600.2600","article-title":"Silvestrol, a rocaglate derivative from the Indonesian plant aglaia foveolata, has significant Bcl-2- and p53-independent anti-tumor activity against chronic lymphocytic leukemia cells","volume":"108","author":"Edwards","year":"2006","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692607000424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692607000424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T23:58:02Z","timestamp":1587859082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692607000424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S1521692607000424"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2007.03.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}